A pilot study of neoajuvant fluorouracil, epirubicin and cyclophosphamide followed by paclitaxel plus high dose toremifene in women with node positive or high-risk breast cancer.
Phase 2
- Conditions
- Primari breast cancer
- Registration Number
- JPRN-UMIN000003091
- Lead Sponsor
- Department of Breast Surgery, Fukushima Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.Case with active other malignancies 2.Case with past history of drug allergy or hypersensitivity 3.Case during pregnancy or lactation 4.Case with adverse myelosuppression 5.Case with infectious disease 6.Case with inflammatory breast cancer 7.Case with metastatic breast cancer 8.Case judged inappropriate by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pathological response rate.
- Secondary Outcome Measures
Name Time Method clinila response rate, adverse events, breast concerving rate.